TY - JOUR T1 - Critically ill COVID-19 associated trait genetics reveals CDK6 inhibitors as potential treatment JF - medRxiv DO - 10.1101/2021.05.18.21256584 SP - 2021.05.18.21256584 AU - Joern E. Klinger AU - Charles N. J. Ravarani AU - Colin Bannard AU - Margaretha R. J. Lamparter AU - Alexander R. E. C. Schwinges AU - Justin L. Cope AU - Hannes A. Baukmann AU - Marco F. Schmidt Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/20/2021.05.18.21256584.abstract N2 - Despite the recent development of vaccines and monoclonal antibodies preventing SARS-CoV-2 infection, treating critically ill COVID-19 patients still remains a top goal. In principle, drug repurposing – the use of an already existing drug for a new indication – could provide a shortcut to a treatment. However, drug repurposing is often very speculative due to the lack of clinical evidence. We here report on a methodology to find and test gene drug target candidates for drug repurposing. We matched critically ill COVID-19 cases from the UK Biobank with healthy controls and screened for significant differences in 33 blood cell types, 30 blood biochemistries, and body mass index in cases and controls. Significant differences in traits that have previously been associated with critically ill COVID-19 status, such as alanine aminotransferase, body mass index, C-reactive protein, and neutrophil cell count were further investigated. In-depth statistical analysis of COVID-19 associated traits and their genetics using regression modeling and propensity score stratification identified cyclin-dependent kinase 6 (CDK6) as a more promising drug target to selectively treat critically ill COVID-19 patients than the previously reported interleukin 6. Four existing CDK6 inhibitors abemaciclib, ribociclib, trilaciclib, and palbociclib have been approved for breast cancer. Clinical evidence for CDK6 inhibitors in treating critically ill COVID-19 has been reported. Further clinical investigations are ongoing.Competing Interest StatementJ.E.K., C.N.J.R., M.R.J.L., H.A.B., J.L.C., and M.F.S are employees of biotx.ai GmbH. A.R.E.S was an employee of biotx.ai GmbH.Funding StatementThe research has been conducted using the UK Biobank Resource under Application no. 36226. We thank Radi Hilaneh for making Fig. 3. The research work was supported by the Investitionsbank des Landes Brandenburg (ILB), the European Regional Development Fund (ERDF), and the European Social Fund+ (ESF+). Access to the UK Biobank was funded by the EIT Health Digital Sandbox program to access European biobank data (grant number 2019-DS1001-3754). We also thank the program digital solutions made in Brandenburg (digisolBB) for its continued support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research has been conducted using the UK Biobank Resource and has been approved by the UK Biobank under Application no. 36226.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFollowing publication of major outputs all anonymised data will be made available on reasonable request to the corresponding author providing this meets local ethical and research governance criteria. ER -